Unicycive Therapeutics (UNCY) Institutional Ownership $0.51 +0.02 (+4.09%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Unicycive Therapeutics (NASDAQ:UNCY)CurrentInstitutional OwnershipPercentage40.42%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$11.12MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$1.54M Get UNCY Insider Trade Alerts Want to know when executives and insiders are buying or selling Unicycive Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data UNCY Institutional Buying and Selling by Quarter Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Unicycive Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/20/2024Virtu Financial LLC73,975$30K0.0%+566.8%0.071% 11/15/2024 XTX Topco Ltd70,784$29K0.0%N/A0.075% 11/14/2024 Walleye Capital LLC5,000,000$2.04M0.0%N/A5.299% 11/14/2024 Acuta Capital Partners LLC1,979,199$807K0.7%N/A2.097% 11/13/2024 Great Point Partners LLC8,559,000$3.49M1.0%N/A9.071% 10/16/2024 Bleakley Financial Group LLC80,000$33K0.0%N/A0.085% 8/20/2024 Nantahala Capital Management LLC2,820,358$1.41M0.1%-15.4%7.499% 7/12/2024 Rosalind Advisors Inc.1,571,200$787K0.6%-16.4%4.178% 5/20/2024Virtu Financial LLC26,082$36K0.0%N/A0.069% 5/16/2024 BVF Inc. IL3,611,601$4.98M0.1%+70.5%9.603% 4/25/2024 Rosalind Advisors Inc.1,879,646$2.59M2.4%N/A5.407% 2/15/2024 BVF Inc. IL2,118,139$1.84M0.0%-37.9%6.095% 11/15/2023 RA Capital Management L.P.3,470,688$2.99M0.1%N/A9.987% 11/8/2023 Vivo Capital LLC3,470,152$2.98M0.4%N/A9.986% 8/10/2023 Ground Swell Capital LLC20,001$26K0.1%N/A0.131% 4/26/2023 Oxbow Advisors LLC11,861$25K0.0%N/A0.078% 2/15/2023 Nantahala Capital Management LLC647,416$350K0.0%-8.9%4.302% 11/15/2022 Board of Trustees of The Leland Stanford Junior University63,019$37K0.0%-74.5%0.419% 11/10/2022 Nantahala Capital Management LLC710,542$419K0.0%-2.6%4.721% 8/15/2022 Nantahala Capital Management LLC729,680$606K0.0%+13.9%4.855% 4/22/2022 Truist Financial Corp37,462$48K0.0%N/A0.250% 11/12/2021 Board of Trustees of The Leland Stanford Junior University247,583$700K0.1%N/A1.707% 11/9/2021BlackRock Inc.11,443$33K0.0%N/A0.079% 10/28/2021 Tandem Capital Management Corp ADV15,500$44K0.0%N/A0.107% (Data available from 1/1/2016 forward) UNCY Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of UNCY shares? During the previous two years, 13 institutional investors and hedge funds held shares of Unicycive Therapeutics. The most heavily invested institutionals were BVF Inc. IL ($4.98M), Great Point Partners LLC ($3.49M), RA Capital Management L.P. ($2.99M), Vivo Capital LLC ($2.98M), Walleye Capital LLC ($2.04M), Nantahala Capital Management LLC ($1.41M), and Acuta Capital Partners LLC ($807K).Learn more on UNCY's institutional investors. What percentage of Unicycive Therapeutics stock is owned by institutional investors? 40.42% of Unicycive Therapeutics stock is owned by institutional investors. Learn more on UNCY's institutional investor holdings. Which institutional investors have been buying Unicycive Therapeutics stock? Of the 12 institutional investors that purchased Unicycive Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Great Point Partners LLC ($8.56M), Walleye Capital LLC ($5M), RA Capital Management L.P. ($3.47M), Vivo Capital LLC ($3.47M), Acuta Capital Partners LLC ($1.98M), Rosalind Advisors Inc. ($1.88M), and BVF Inc. IL ($1.49M). How much institutional buying is happening at Unicycive Therapeutics? Institutional investors have bought a total of 26,123,756 shares in the last 24 months. This purchase volume represents approximately $17.14M in transactions. Which Unicycive Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Unicycive Therapeutics stock in the last 24 months: BVF Inc. IL ($1.30M), Nantahala Capital Management LLC ($578.35K), and Rosalind Advisors Inc. ($308.45K). How much institutional selling is happening at Unicycive Therapeutics? Institutional investors have sold a total of 2,182,224 shares in the last 24 months. This volume of shares sold represents approximately $1.57M in transactions. Related Companies Enanta Pharmaceuticals Major Shareholders Neurogene Major Shareholders Lexeo Therapeutics Major Shareholders Compass Therapeutics Major Shareholders ADC Therapeutics Major Shareholders Opthea Major Shareholders Heron Therapeutics Major Shareholders Inozyme Pharma Major Shareholders Caribou Biosciences Major Shareholders Tenaya Therapeutics Major Shareholders This page (NASDAQ:UNCY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
